Previous 10 | Next 10 |
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder, major depressive...
Alzamend Neuro ( NASDAQ: ALZN ) has announced receipt of a “ Study May Proceed ” letter from the U.S. FDA for a phase I/IIA clinical trial under its Investigational New Drug application for an immunotherapy to treat mild to moderate dementia of the Alzheimer ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (&...
Alzamend Neuro ( NASDAQ: ALZN ) said it began dosing healthy people in a phase 2A study of oral drug AL001 treat people with dementia related to Alzheimer’s. The placebo-controlled trial (AL001-02) started in May to evaluate the safety and tolerability of AL001 ...
Alzamend pursuing additional indications of bipolar disorder, major depressive disorder and post-traumatic stress disorder for AL001 Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developin...
Clinical-stage biopharma Alzamend Neuro ( NASDAQ: ALZN ) on Thursday said it had submitted an investigational new drug (IND) application to the U.S. FDA for a phase 1/2A trial of its immunotherapy product candidate ALZN002 for the treatment of dementia of the Alzheimer's type....
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (&...
Why Are Alzheimer’s Stocks Up Today? This article discusses a handful of penny stocks with exposure to potential Alzheimer’s disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB )...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (&...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in penny stocks know that they are an inherently risky proposition. That goes double for any investor just getting into this market. But with great risk comes great reward. In this case, I think these are penny s...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...